Blueprint MedicinesBPMC
13F holders, Q3 2025 (September 30)5holders −351
0new positions
345sold out
$98.70avg. 13F price*
At the end of Q3 2025, 5 institutions reported holding Blueprint Medicines Corp. (BPMC) in their 13F filings, down 351 from Q2 2025. 0 opened new positions and 345 sold out. The largest holders were DekaBank Deutsche Girozentrale ($2.5M), Van Eck Associates Corp. ($17K) and IFP Advisors, Inc ($9K).
- Company
- Blueprint Medicines Corp.
- CUSIP
- 09627Y109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 345 | $8.5B |
All 13F filers, Q2 2025 → Q3 2025: 16 shares bought and 66,363,863 shares sold, net −66,363,847 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| DekaBank Deutsche Girozentrale | 0.00% | No change | 25,883 | $2.5M |
| Van Eck Associates Corp. | 0.00% | Reduce -86.8% | 132 | $17K |
| IFP Advisors, Inc | 0.00% | Add +32.0% | 66 | $9K |
| Osaic Holdings, Inc. | 0.00% | Reduce -91.7% | 23 | $3K |
| Huntington National Bank | 0.00% | Reduce -99.5% | 1 | $129 |
"% of holder's portfolio" is BPMC's weight in each manager's 13F, not the share of Blueprint Medicines Corp. the manager owns.